Floatz logo

PREDNISONE TABLETS

Recurrent Osteosarcoma

Children's Oncology GroupSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

19 Active assets in the Recurrent Osteosarcoma cohort.

Asset / SponsorPhaseRating
Cediranib
National Cancer Institute (NCI)
Phase 2BBB
Eloxatin
National Cancer Institute (NCI)
Phase 2BB
Ipilimumab
Children's National Research Institute
Phase 2BB
Olaparib
Fundación de investigación HM
Phase 2BB
Irinotecan
National Cancer Institute (NCI)
Phase 2BB

View all 30 →

Same molecule, other indications

PREDNISONE TABLETS is also rated in:

Recurrent Adult T-cell Leukemia/LymphomaDormant
BBB
Indicative ·
76 / 100
View asset →
diffuse large B-cell lymphomaDormant
BBB
Indicative ·
74 / 100
View asset →
metastatic prostate carcinomaDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →